Vrovwen Biologics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 6 Year, 19 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.90 M
as on 13-12-2024
- Revenue 88.30%
(FY 2021)
- Profit 136.99%
(FY 2021)
- Ebitda 332.37%
(FY 2021)
- Net Worth 23.99%
(FY 2021)
- Total Assets 17.32%
(FY 2021)
About Vrovwen Biologics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.90 M.
Monita Anand and Satbir Anand serve as directors at the Company.
- CIN/LLPIN
U24304CH2018PTC042313
- Company No.
042313
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vrovwen Biologics Private Limited offer?
Vrovwen Biologics Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Common Disease Medicines, Allopathic Cough Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Anti Infective Agent, Cefpodoxime Proxetil Oral Suspension.
Who are the key members and board of directors at Vrovwen Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satbir Anand  | Director | 28-Dec-2018 | Current |
| Monita Anand | Director | 28-Dec-2018 | Current |
Financial Performance of Vrovwen Biologics.
Vrovwen Biologics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 88.3% increase. The company also saw a substantial improvement in profitability, with a 136.99% increase in profit. The company's net worth Soared by an impressive increase of 23.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vrovwen Biologics?
Unlock access to Vrovwen Biologics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 May 2024 | ₹2.50 M | Open |
Others Creation Date: 06 Oct 2021 | ₹1.40 M | Open |
How Many Employees Work at Vrovwen Biologics?
Unlock and access historical data on people associated with Vrovwen Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vrovwen Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vrovwen Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
